GlassScriptPhysician profile
Rodney Barry Stout
NPI 1184668253
$1,676.04
in general payments reported to CMS, 2019-2025
27 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.79 · 2020: $75.62 · 2021: $317 · 2022: $293 · 2023: $364 · 2024: $278 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $372.67 | 2020-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $180.35 | 2021-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $168.74 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $127.12 | 2019-2023 | Prolia, Evenity |
| Abbott Laboratories | $95.72 | 2021-2024 | Freestyle Libre 3 |
| Insulet Corporation | $80.00 | 2019-2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $68.87 | 2021-2024 | |
| Lilly USA, LLC | $68.39 | 2021-2023 | Mounjaro, Humulin, Trulicity |
| Xeris Pharmaceuticals, INC. | $58.90 | 2022-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $48.00 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.63 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $41.35 | 2021-2023 | Farxiga |
| Medtronic, INC. | $35.27 | 2022 | |
| Biogen, INC. | $30.48 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.79 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $28.35 | 2024-2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $27.97 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $20.95 | 2024 | Voxzogo 1.2mg |
| Globus Medical, INC. | $20.62 | 2025 | Senza |
| Rgh Enterprises LLC | $19.67 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.30 | 2021 | |
| Mannkind Corporation | $18.40 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.10 | 2021 | |
| Abbvie INC. | $15.48 | 2022 | |
| Averitas Pharma INC. | $13.34 | 2023 | Qutenza |
| Nestle Healthcare Nutrition INC. | $13.14 | 2023 | |
| Recordati_rare_diseases_inc. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.